Sökning: WFRF:(Bergh Thorén Fredrik 1976) > Dynamics of cytotox...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 05828naa a2200757 4500 | |
001 | oai:gup.ub.gu.se/233422 | |
003 | SwePub | |
008 | 240910s2016 | |||||||||||000 ||eng| | |
009 | oai:research.chalmers.se:5861481a-7ddc-4111-9bda-9e1a22abfc1c | |
009 | oai:lup.lub.lu.se:df9c01bb-63aa-4b6c-9d67-ca8ade09c469 | |
024 | 7 | a https://gup.ub.gu.se/publication/2334222 URI |
024 | 7 | a https://doi.org/10.18632/oncotarget.72102 DOI |
024 | 7 | a https://research.chalmers.se/publication/2334222 URI |
024 | 7 | a https://lup.lub.lu.se/record/88258732 URI |
040 | a (SwePub)gud (SwePub)cthd (SwePub)lu | |
041 | a eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Sander, Frida Ewaldu Gothenburg University,Göteborgs universitet,Sahlgrenska Cancer Center,University of Gothenburg4 aut |
245 | 1 0 | a Dynamics of cytotoxic T cell subsets during immunotherapy predicts outcome in acute myeloid leukemia |
264 | c 2016-02-05 | |
264 | 1 | b Impact Journals, LLC,c 2016 |
520 | a Preventing relapse after chemotherapy remains a challenge in acute myeloid leukemia (AML). Eighty-four non-transplanted AML patients in first complete remission received relapse-preventive immunotherapy with histamine dihydrochloride and low-dose interleukin-2 in an international phase IV trial (ClinicalTrials.gov; NCT01347996). Blood samples were drawn during cycles of immunotherapy and analyzed for CD8(+) (cytotoxic) T cell phenotypes in blood. During the first cycle of therapy, a re-distribution of cytotoxic T cells was observed comprising a reduction of T effector memory cells and a concomitant increase of T effector cells. The dynamics of T cell subtypes during immunotherapy prognosticated relapse and survival, in particular among older patients and remained significantly predictive of clinical outcome after correction for potential confounders. Presence of CD8(+) T cells with specificity for leukemia-associated antigens identified patients with low relapse risk. Our results point to novel aspects of T cell-mediated immunosurveillance in AML and provide conceivable biomarkers in relapse-preventive immunotherapy. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicin0 (SwePub)3022 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicine0 (SwePub)3022 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Hematologi0 (SwePub)302022 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Hematology0 (SwePub)302022 hsv//eng |
653 | a acute myeloid leukemia | |
653 | a immunotherapy | |
653 | a cytotoxic T cells | |
653 | a antigen-specific T cells | |
653 | a Immunology and | |
653 | a histamine dihydrochloride | |
653 | a transplantation | |
653 | a memory | |
653 | a differentiation | |
653 | a interleukin-2 | |
653 | a lymphocytes | |
653 | a maintenance | |
653 | a remission | |
653 | a responses | |
653 | a effector | |
653 | a Oncology | |
653 | a Cell Biology | |
653 | a lymphocytes | |
700 | 1 | a Rydström, Anna,d 1976u Gothenburg University,Göteborgs universitet,Sahlgrenska Cancer Center,University of Gothenburg4 aut0 (Swepub:gu)xrydsa |
700 | 1 | a Bernson, Elin,d 1987u Gothenburg University,Göteborgs universitet,Sahlgrenska Cancer Center,University of Gothenburg4 aut0 (Swepub:cth)bernson |
700 | 1 | a Kiffin, Robertau Gothenburg University,Göteborgs universitet,Sahlgrenska Cancer Center,University of Gothenburg4 aut0 (Swepub:gu)xkifro |
700 | 1 | a Riise, Rebecca E,d 1987u Gothenburg University,Göteborgs universitet,Sahlgrenska Cancer Center,University of Gothenburg4 aut0 (Swepub:gu)xriire |
700 | 1 | a Aurelius, Johan,d 1980u Gothenburg University,Göteborgs universitet,Sahlgrenska Cancer Center,Institutionen för medicin, avdelningen för invärtesmedicin och klinisk nutrition,Institute of Medicine, Department of Internal Medicine and Clinical Nutrition,University of Gothenburg4 aut0 (Swepub:gu)xaurjo |
700 | 1 | a Anderson, Haraldu Lund University,Lunds universitet,Medicinsk onkologi,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Medical oncology,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)onk-han |
700 | 1 | a Brune, Mats,d 1950u Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för invärtesmedicin och klinisk nutrition,Institute of Medicine, Department of Internal Medicine and Clinical Nutrition,University of Gothenburg4 aut0 (Swepub:gu)xbrunm |
700 | 1 | a Foa, R.4 aut |
700 | 1 | a Hellstrand, Kristoffer,d 1956u Gothenburg University,Göteborgs universitet,Sahlgrenska Cancer Center,University of Gothenburg4 aut0 (Swepub:gu)xhellk |
700 | 1 | a Bergh Thorén, Fredrik,d 1976u Gothenburg University,Göteborgs universitet,Sahlgrenska Cancer Center,University of Gothenburg4 aut0 (Swepub:gu)xthofr |
700 | 1 | a Martner, Anna,d 1979u Gothenburg University,Göteborgs universitet,Sahlgrenska Cancer Center,University of Gothenburg4 aut0 (Swepub:gu)xbigan |
710 | 2 | a Göteborgs universitetb Sahlgrenska Cancer Center4 org |
773 | 0 | t Oncotargetd : Impact Journals, LLCg 7:7, s. 7586-7596q 7:7<7586-7596x 1949-2553 |
856 | 4 | u http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=7210&path%5B%5D=20575 |
856 | 4 | u http://dx.doi.org/10.18632/oncotarget.7210y FULLTEXT |
856 | 4 | u http://www.ncbi.nlm.nih.gov/pubmed/26863635?dopt=Abstractx freey FULLTEXT |
856 | 4 8 | u https://gup.ub.gu.se/publication/233422 |
856 | 4 8 | u https://doi.org/10.18632/oncotarget.7210 |
856 | 4 8 | u https://research.chalmers.se/publication/233422 |
856 | 4 8 | u https://lup.lub.lu.se/record/8825873 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy